UY25436A1 - Combinaciones de estatina-inhibidor de mmp - Google Patents

Combinaciones de estatina-inhibidor de mmp

Info

Publication number
UY25436A1
UY25436A1 UY25436A UY25436A UY25436A1 UY 25436 A1 UY25436 A1 UY 25436A1 UY 25436 A UY25436 A UY 25436A UY 25436 A UY25436 A UY 25436A UY 25436 A1 UY25436 A1 UY 25436A1
Authority
UY
Uruguay
Prior art keywords
mmp inhibitor
statin
inhibitor combinations
combination
ldl
Prior art date
Application number
UY25436A
Other languages
English (en)
Spanish (es)
Inventor
Newton Roger Schofield Y David
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY25436A1 publication Critical patent/UY25436A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY25436A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp UY25436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
UY25436A1 true UY25436A1 (es) 2001-10-25

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25436A UY25436A1 (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp

Country Status (18)

Country Link
EP (1) EP1063991A1 (ko)
JP (1) JP2002506818A (ko)
KR (1) KR20010041916A (ko)
AR (1) AR018113A1 (ko)
AU (1) AU1591699A (ko)
BR (1) BR9815745A (ko)
CA (1) CA2309588A1 (ko)
CO (1) CO5070670A1 (ko)
GT (1) GT199900039A (ko)
HN (1) HN1999000029A (ko)
MY (1) MY140504A (ko)
NZ (1) NZ505994A (ko)
PA (1) PA8469001A1 (ko)
PE (1) PE20000348A1 (ko)
SV (1) SV1999000026A (ko)
UY (1) UY25436A1 (ko)
WO (1) WO1999047138A1 (ko)
ZA (1) ZA992106B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
RU2410118C2 (ru) 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611410A (pt) * 1995-11-02 1999-01-05 Warner Lambert Co Método e composição farmacêutica para regular a concentração de lipídios
PL186416B1 (pl) * 1996-05-17 2004-01-30 Warner Lambert Co Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek
IL128545A0 (en) * 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
PA8469001A1 (es) 2002-09-17
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23
BR9815745A (pt) 2000-11-14
NZ505994A (en) 2003-10-31
JP2002506818A (ja) 2002-03-05
SV1999000026A (es) 2000-01-18
CO5070670A1 (es) 2001-08-28
GT199900039A (es) 2000-09-06
HN1999000029A (es) 1999-09-29
KR20010041916A (ko) 2001-05-25
ZA992106B (en) 1999-09-30
MY140504A (en) 2009-12-31
AR018113A1 (es) 2001-10-31
WO1999047138A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03
PE20000348A1 (es) 2000-05-22

Similar Documents

Publication Publication Date Title
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
UY25268A1 (es) Inhibicion de la oxidacion de lipoproteinas
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
EA200100707A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
EA199800667A1 (ru) Новые фенантридины
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
UY25299A1 (es) Combinaciones de estatina-eter carboxialquílico
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
ECSP034782A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
EP0793489A4 (en) AGENTS FOR TREATING SKIN DISEASES
EE200100155A (et) Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
UY25436A1 (es) Combinaciones de estatina-inhibidor de mmp
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
PT1152757E (pt) Inibidores de mmp no amolecimento do tecido conjuntivo
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110104